Evidence for maximal treatment of atherosclerosis: Drastic reduction of cholesterol and fibrinogen restores vascular homeostasis

Therapeutic Apheresis

Volumn 5, Issue 3, 2001, Pages 207-211

  Jaeger, Beate Roxane ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; Coronary artery disease; Fibrinogen; Heart transplantation; Low density lipoprotein apheresis; Low density lipoprotein cholesterol

Indexed keywords

ANTILIPEMIC AGENT; CARBON DIOXIDE; CHOLESTEROL; FIBRINOGEN; FIBRINOGEN RECEPTOR; HEPARIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXYGEN;

APHERESIS; ARTERIOSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; ERYTHROCYTE AGGREGATION; FAMILIAL HYPERCHOLESTEROLEMIA; HEARING LOSS; HEART MUSCLE BLOOD FLOW; HEART TRANSPLANTATION; HOMEOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; MICROCIRCULATION; PLASMA VISCOSITY; PRIORITY JOURNAL; RETINA ISCHEMIA; VASOMOTOR REFLEX;

ADULT; ARTERIOSCLEROSIS; BLOOD COMPONENT REMOVAL; CHILD; CHOLESTEROL, LDL; ENDOTHELIUM, VASCULAR; EXTRACORPOREAL CIRCULATION; FIBRINOGEN; FIBRINOLYTIC AGENTS; HEPARIN; HOMEOSTASIS; HUMANS; LIPOPROTEIN(A);

EID: 0034947382     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2001.00289.x     Document Type: Article

References (28)

1. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months
2. The HELP-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease
3. The HELP system, a new therapeutic tool in the treatment of atherosclerosis
4. Low density lipoprotein plasmapheresis with and without Lowastatin in the treatment of the homozygous form of familial hypercholesterolemia
5. Improvement of coronary vasodilation capacity through single LDL apheresis
6. Regression of transplant coronary artery disease during chronic LDL-apheresis
7. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation
8. Heparin-induced extracorporeal LDL/fibrinogen precipitation - HELP - In coronary and cerebral ischemia
9. Improved recovery of cerebral infarctions after plasmapheretic reduction of lipids and fibrinogen
10. The pathogenesis of atherosclerosis. A perspective for the 1990s
11. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology
12. The release of an immobilized lipoprotein fraction from atherosclerotic lesions by incubation with plasmin
13. Impact of lipids on progression and regression of atherosclerosis
14. Increased thromboxane biosynthesis in type IIa hypercholesterolemia
15. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men
16. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
17. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin survival study (4S)
18. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the second joint task force of European and other societies on coronary prevention
19. Collaborative overview of randomised trials of antiplatelet therapy-1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
20. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
21. 2-reactivity after heparin-mediated extracorporeal LDL precipitation in patients with coronary heart disease and hypercholesterolemia
22. Improved hemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation (HELP)
23. Consistent lowering of clotting factors for the treatment of acute cardiovascular syndromes and hypercoagulability-A different pathophysiologic approach
24. Akute wirkungen der extrakorporalen LDL-cholesterin- und fibrinogen-elimination auf blutrheologie und mikrozirkulation
25. Heparin-induced extracorporeal Low-density-lipoprotein precipitation (HELP) to improve the recovery of hearing in patients with sudden idiopathic hearing loss
26. HELP apheresis in the treatment of sepsis
27. An extracorporeal device to remove clotting factors from the blood circulation via precipitation with heparin (HELP)
28. Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated with heparin-induced extracorporeal LDL precipitation (HELP)